Compile Data Set for Download or QSAR
maximum 50k data
Found 67 with Last Name = 'puerta' and Initial = 'dt'
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase()
Forge Therapeutics

US Patent
LigandPNGBDBM50200120(CHEMBL260091 | CHIR-090 | US10875832, Compound ChI...)
Affinity DataIC50: <1nMAssay Description:LpxC inhibition assays were performed using liquid chromatography with tandem mass spectrometry. Assays were performed, in duplicate, in opaque, 96-w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563144(US11407740, Compound 17)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563146(US11407740, Compound 19 | US11407740, Compound 20)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563154(US11407740, Compound 38)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563255(US11407740, Compound 65)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563259(US11407740, Compound 130)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563262(US11407740, Compound 139)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563263(US11407740, Compound 141)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563267(US11407740, Compound 169)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563268(US11407740, Compound 171)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563269(US11407740, Compound 172)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563273(US11407740, Compound 191)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563275(US11407740, Compound 193)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563294(US11407740, Compound 289)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563298(US11407740, Compound 299)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563124(US11407740, Compound 7)
Affinity DataIC50: <10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563125(US11407740, Compound 14)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563152(US11407740, Compound 23)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563155(US11407740, Compound 43)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563156(US11407740, Compound 44)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563160(US11407740, Compound 54)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563174(US11407740, Compound 56)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563175(US11407740, Compound 57)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563180(US11407740, Compound 60)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563254(US11407740, Compound 64)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563256(6-(3-(((S)-1-fluoropropan-2-yl)amino)-2-(4-((4-((3...)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563257(US11407740, Compound 71)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563258(US11407740, Compound 101)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563261(US11407740, Compound 138)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563265(US11407740, Compound 148)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563270(US11407740, Compound 173)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563271(US11407740, Compound 174)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563272(US11407740, Compound 177)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563274(US11407740, Compound 192)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563276(US11407740, Compound 194)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563277(US11407740, Compound 199)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563279(US11407740, Compound 201)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563280(US11407740, Compound 202)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563285(US11407740, Compound 209)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563286(US11407740, Compound 210)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563287(US11407740, Compound 211)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563292(US11407740, Compound 287)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563293(US11407740, Compound 288)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563295(US11407740, Compound 296)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli)
Forge Therapeutics

US Patent
LigandPNGBDBM563296(US11407740, Compound 297)
Affinity DataIC50:  30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase()
Forge Therapeutics

US Patent
LigandPNGBDBM476343(US10875832, Compound 98)
Affinity DataIC50:  55nMAssay Description:LpxC inhibition assays were performed using liquid chromatography with tandem mass spectrometry. Assays were performed, in duplicate, in opaque, 96-w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase()
Forge Therapeutics

US Patent
LigandPNGBDBM476342(US10875832, Compound 97)
Affinity DataIC50:  55nMAssay Description:LpxC inhibition assays were performed using liquid chromatography with tandem mass spectrometry. Assays were performed, in duplicate, in opaque, 96-w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 67 total ) | Next | Last >>
Jump to: